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Objective: Human bocavirus (HBoV) is a recently discovered parvovirus associated with acute 
respiratory tract infections in children. The objective of the present study was to determine the 
frequency and clinical relevance of HBoV infection in adult patients with acute exacerbation 
of chronic obstructive pulmonary disease (AE-COPD).
Methods: We retrospectively tested 212 COPD patients, 141 (66.5%) with AE-COPD and 
71 (33.5%) with stable disease, of whom nasal lavage and induced sputum had been obtained 
for the presence of HBoV deoxyribonucleic acid (DNA). The speciﬁ  city of positive polymerase 
chain reaction results was conﬁ  rmed by sequencing.
Results: Two hundred two of 212 patients for whom PCR results were available both for nasal 
lavage and induced sputum samples were eligible for data analysis. HBoV DNA was detected 
in three patients (1.5%). Of those, only one patient had AE-COPD. Thus, the frequency of 
HBoV infection demonstrated to be low in both AE-COPD (0.8%) and stable COPD (2.9%). 
HBoV was found in two sputum and one nasal lavage sample in different patients, respectively. 
Sequencing revealed 99% sequence identity with the reference strain.
Conclusion: HBoV detection was infrequent. Since we detected HBoV in both upper and 
lower respiratory tract specimens and in AE-COPD as well as stable disease, a major role of 
HBoV infection in adults with AE-COPD is unlikely.
Keywords:  acute exacerbation, acute respiratory tract infection, chronic obstructive pulmonary 
disease, emerging respiratory virus, epidemiology, human bocavirus
Introduction
Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) account 
for a signiﬁ  cant number of hospitalizations and therefore present an important 
economic burden in health care.1 AE-COPD substantially contribute to loss in 
lung function, disease progression, and mortality.2 Most patients presenting with 
AE-COPD describe symptoms of respiratory infection.3 Historically, bacteria have 
been considered to be the major cause of infectious exacerbations, but as bacteria 
are also found in clinically stable patients, the role of bacterial infection remains 
controversial.4
With the broad availability of molecular diagnostics like polymerase chain reac-
tion (PCR) the prominent contribution of common viral agents of upper respiratory 
tract infection like human rhinovirus (HRV) and respiratory syncytial virus (RSV) to 
the etiology of AE-COPD has been increasingly recognized.4–6 Nevertheless, in about 
one third of severe exacerbations the cause remains unknown.1 In recent years novel 
respiratory viruses including the human metapneumovirus (HMPV) and several coro-
naviruses (SARS, NL63, and HKU1) have been discovered. Their role in AE-COPD 
has already been deﬁ  ned to some extent.7,8International Journal of COPD 2009:4 112
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Human bocavirus (HBoV) is a novel parvovirus initially 
discovered in 2005 in respiratory secretions of Swedish 
children with symptoms of upper and lower respiratory tract 
infection with a frequency of 3.1%.9 Proving its role as a caus-
ative agent of acute respiratory tract infections is challenging 
as HBoV has not been propagated in cell culture and as 
animal models have not yet been established. Hence, some 
of the modiﬁ  ed postulates of Koch are not applicable.10
Numerous retrospective and prospective studies suggested 
an association between HBoV and acute respiratory tract 
infections in children. Clinical ﬁ  ndings consisted of wheezing 
episodes, asthma exacerbations, acute obstructive bronchitis, 
bronchiolitis, croup, and pneumonia.11–15 Infants below the age 
of two years and patients with structural pulmonary diseases 
or immune disorders seem to be predominantly affected. Pre-
liminary evidence is provided that acute HBoV infection may 
take a viremic course and may also be capable of persistence 
in the respiratory tract.16 HBoV infections appear endemic 
worldwide.16 First studies on the seroepidemiology give evi-
dence for protection by maternal antibodies within the ﬁ  rst 
months of life.17 In a Japanese study all of the 204 children 
examined had immunoglobulin G antibodies to the viral pro-
tein 1 (VP1) by the age of 6 years, emphasizing its ubiquitous 
nature.18 Taken together, these ﬁ  ndings suggest that there is 
protective immunity after past infection which may explain 
why HBoV is comparatively rare in adults.9,19–22 Frequencies of 
HBoV detection in respiratory specimens of children described 
in the literature vary from 2% to 19%.11,23 Recently, a HBoV 
detection rate of 12% has been described among German chil-
dren with symptoms of respiratory tract infections.24
To our knowledge the role of HBoV in a well character-
ized population of adult patients with AE-COPD has not 
been systematically studied yet. Implications of a frequent 
detection in AE-COPD are the introduction in clinical routine 
testing and a subsequent decrease of antimicrobial overuse. 
The aim of the present study was to determine the prevalence 
of HBoV infection in hospitalized patients with AE-COPD 
and to establish its potential clinical relevance by comparison 
to patients with stable COPD hospitalized for other reasons 
than acute exacerbation.
Material and methods
Study design, subjects, and samples
We retrospectively tested two groups of COPD patients for the 
presence of HBoV deoxyribonucleic acid (DNA). 212 patients, 
141 (66.5%) with AE-COPD and a control group of 71 (33.5%) 
COPD patients with stable disease were selected for evalua-
tion. These subjects had been enrolled between October 1999 
and April 2003 in a prospective case-control manner in a 
2:1 ratio. In order to prevent seasonal selection bias subjects 
had been recruited in a 2:1 ratio each month.
Inclusion criteria for both groups were age of 18 to 
85 years, exacerbated or stable COPD, chronic airﬂ  ow limita-
tion (forced expiratory volume in one second [FEV1] 80% 
predicted), admission to hospital and written informed 
consent. Exclusion criteria for both groups were bronchial 
asthma and dyspnea of other origin (pneumonia, tuberculosis, 
pulmonary ﬁ  brosis, bronchiectasis, lung cancer, or conges-
tive heart failure).
The collection of demographic and clinical data, the 
standardized collection and processing of nasal lavage and 
induced sputum samples, the assessment of lung function, 
the evaluation of chest radiographs and underlying common 
deﬁ  nitions have been described in detail.25 Brieﬂ  y, COPD 
and AE-COPD were deﬁ  ned as by the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD).1 AE-COPD 
was characterized by worsening of dyspnea, cough and/or 
sputum expectoration beyond normal day-to-day variations 
and was acute in onset. Patients with stable COPD did not 
experience an exacerbation within the last 30 days prior 
to hospital admission, had no changes in inhaled or oral 
medication within the last 14 days and had been admitted 
for other conditions into medical departments other than 
pulmonary care.
The following variables were selected for data analysis: 
age, gender, body mass index, smoking behavior, smoking 
history in pack years, oral and inhaled steroid medication 
before admission, dose of oral steroid medication, where 
applicable, C-reactive protein and white blood count values, 
clinical symptoms on admission, comorbidity, and COPD 
status. Spirometric data were assessed on admission for both 
groups and before discharge in patients with AE-COPD: 
FEV1 in liters and % predicted, forced vital capacity (FVC 
in liters and % predicted) and FEV1/FVC.
Both nasal lavage and induced sputum samples had been 
obtained from each patient between 1999 and 2003 and 
stored at −70 °C until DNA extraction was performed. Viral 
coinfections with other common respiratory viruses (HMPV, 
HRV, inﬂ  uenza viruses A and B, parainﬂ  uenza virus 3, and 
RSV) were determined by sensitive real-time PCR assays 
for all patients in nasal lavage and induced sputum samples 
as previously published.7,25–28
HBoV PCR and sequencing
DNA was extracted from 250 μl of induced sputum 
and nasal lavage samples using QIAamp DNA Blood International Journal of COPD 2009:4 113
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Mini Kit (Qiagen, Hilden, Germany) according to the 
instructions of the manufacturer. Elution volume was 
50 μl. Extracted DNA samples were stored at −20 °C for 
further analysis. HBoV DNA ampliﬁ  cation was performed 
with the nonstructural protein 1 (NP-1) primers BoV188F 
(5'-GAGCTCTGTAAGTACTATTAC-3') and BoV542R 
(5'-CTCTGTGTTGACTGAATACAG-3') described by 
Allander and colleagues9 using the HotStarTaq DNA poly-
merase (Qiagen, Hilden, Germany). PCR reactions were 
carried out in a 50 μl volume consisting of 5 μl extracted 
DNA, 1 × Qiagen HotStar buffer, dNTPs at a ﬁ  nal concen-
tration of 200 μM each, 200 pmol of each primer, and 1.5 U 
of Taq polymerase as previously described by Weissbrich 
and colleagues.29 Cycling conditions were 50 cycles (94 °C 
30 s, 53 °C 40 s and 1 min at 72 °C) after a preheating step 
of 10 min at 95 °C.
PCR products were visualized by staining with ethidium 
bromide by agarose gel electrophoresis considering a positive 
PCR reaction when a band of the expected size of 354 base 
pairs (bp) was detected. Sequence speciﬁ  city was conﬁ  rmed 
by sequencing all positive PCR products in both directions 
using Big Dye terminator chemistry and the ABI Prism 3100 
(Applied Biosystems, Darmstadt, Germany).
The laboratory team was blinded to the patient’s COPD 
status. Strict laboratory procedures were implemented to 
prevent PCR contamination. One negative control was ampli-
ﬁ  ed for every ﬁ  ve samples. A plasmid containing 5182 bp 
of HBoV DNA, isolate Stockholm 2 (ST2) [GenBank: 
DQ000496] cloned in the vector pCR4-TOPO® (Invitrogen, 
Paisley, UK) was used as positive control. Sensitivity of the 
HBoV PCR assay was assessed by dilution series and was 
determined to a single copy of viral genome per reaction.
Statistical analysis
Data analysis was performed using SPSS, version 11.5 (SPSS 
Inc., Chicago, IL, USA). Categorical data were compared by 
Pearson’s chi-squared or Fisher’s exact test, where appropri-
ate. Normal distribution in continuous variables was deter-
mined with the Kolmogorov–Smirnov test and differences 
were subsequently determined either with student’s t-test or 
Mann–Whitney U test. All p values reported were calculated 
two-sided with statistical signiﬁ  cance set to p  0.05.
The study protocol was approved by the ethics committee 
of the Ruhr University, Bochum, Germany. All study 




From October 1999 to April 2003 induced sputum and nasal 
lavage samples from 212 hospitalized COPD patients, 141 
with acute exacerbation and 71 with stable disease, had been 
obtained in a case-control setup in a 2:1 ratio. Of those, 
PCR results for the presence of HBoV DNA were avail-
able both for induced sputum and nasal lavage specimens 
in 202 patients, 134 with acute exacerbation and 68 with 
stable disease, who constituted the actual study population 
(Figure 1). Ten subjects were excluded from data analysis 
as two induced sputum and eight nasal lavage samples were 
not sufﬁ  cient for PCR experiments.
202 patients eligible for data analysis:
• 134 AE-COPD patients 
• 68 controls with stable COPD 
PCR results available both for induced 
sputum and nasal lavage specimen!
10 patients excluded due to insufficient 
material for PCR analysis:
• 2 induced sputum samples
• 8 nasal lavage samples  
212 COPD patients selected from a 
previous, prospective case-control study:  
• 141 AE-COPD patients 
• 71 controls with stable COPD 
Figure 1 Study proﬁ  le.
Abbreviations:  AE-COPD, acute exacerbation of chronic obstructive pulmonary disease; PCR, polymerase chain reaction.International Journal of COPD 2009:4 114
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The demographic and clinical features of the study 
population are shown in Table 1. The two groups were compa-
rable in terms of age, sex, body mass index, smoking behavior, 
pack years, and frequency of inhaled and oral steroid medi-
cation. The age distribution in the AE-COPD group ranged 
from 41 to 83 and from 43 to 81 years in the control group. 
Signiﬁ  cant differences were apparent for increased airﬂ  ow 
limitation on admission (FEV1 in liters and % predicted), 
higher inﬂ  ammatory laboratory parameters indicating infection 
(CRP and leukocytes) and higher doses of administered oral 
steroids before admission in the AE-COPD group. Spirometric 
data before discharge were available for 84 of 134 patients 
(62.7%) with AE-COPD, had signiﬁ  cantly improved after 
treatment for acute exacerbation and were comparable to the 
baseline airﬂ  ow in the control group (Table 1).
Prevalence of HBoV infection
Three of 202 patients (1.5%) tested for HBoV DNA were 
found to be positive by PCR and subsequent sequencing. Of 
these subjects only one had an acute exacerbation, the other 
two had stable, but (very) severe COPD (Table 2). Thus, 
the frequency of HBoV detection demonstrated to be low 
in both AE-COPD (1/134, 0.8%) and stable COPD (2/68, 
2.9%). In two out of 202 patients (1.0%) HBoV was detected 
in induced sputum samples, whereas only one nasal lavage 
sample (1/202, 0.5%) tested positive for HBoV.
Table 1 Demographic and clinical characteristics of the study population
Variables AE-COPD Stable COPD P valuea
n% d n% d
Patients (total n = 202) 134 66.3 68 33.7
n% e n% e
Sex
 Female 29 21.6 11 16.2 0.46
 Male 105 78.4 57 83.8
Smoking behavior
 Active  smokers 32 23.9 21 30.9 0.18
 Nonsmoker 24 17.9 6 8.3
 Ex-smoker 78 58.2 41 60.3
Oral steroid medication
 Yes 93 69.4 42 61.8 0.34
 No 41 30.6 26 38.2
Inhaled corticosteroids
 Yes 87 64.9 48 70.6 0.44
 No 47 35.1 20 29.4
Mean SD Mean SD
Age (years) 67.8 8.7 65.3 10.8 0.22
Body mass index (kg/m2) 27.2 5.4 27.4 5.3 0.80
Median Range Median Range
Pack yearsb 30.0 2–120 30.0 2–120 0.65
FEV1ad (L) 1.0 0.4–2.2 1.2 0.5–2.6 0.0001
FEV1ad (% predicted) 36.8 16.7–79.0 43.4 19.4–77.3 0.001
FEV1dis (L) 1.2 0.6–2.9 1.2 0.5–2.6 1.00
FEV1dis (% predicted) 45.2 18.5–78.9 43.4 19.4–77.3 0.41
CRP (mg/dL) 0.9 0.0–39.8 0.6 0.0–12.9 0.0005
Leukocytes/nL 10.9 0.7–27.2 10.2 5.1–24.0 0.031
Oral steroid dose (mg)c 10 0–150 5 0–150 0.040
Notes: aP values with statistical signiﬁ  cance are printed in bold. bPack years in active and ex-smokers. cOral steroid dose in prednisone equivalent before admission. dPercent 
in line. ePercent in column.
Abbreviations: (AE-) COPD, (acute exacerbation of) chronic obstructive pulmonary disease; CRP, C-reactive protein; FEV1ad, forced expiratory volume in one second on 
admission; FEV1dis, baseline forced expiratory volume in one second for the control group and before discharge after recovery from exacerbation for the AE-COPD group; 
SD, standard deviation.International Journal of COPD 2009:4 115
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Clinical features of HBoV-positive 
subjects
The clinical features of the three patients positive for HBoV 
are shown in Table 2. HBoV was found in two sputum 
samples and one nasal lavage sample, while corresponding 
nasal lavage and sputum samples were negative, respec-
tively. All patients were male and presented in the winter/
spring season (March and November 2000, January 2002). 
They showed no inﬁ  ltrations on chest X-ray, had moder-
ately to very severely impaired lung function according to 
GOLD stages II–IV and reported various comorbidities 
(arterial hypertension, cor pulmonale, obstructive sleep 
apnea, cardiomyopathy and ischemic stroke). Two subjects 
had stable COPD and reported cough, whitish expectora-
tion and dyspnea on exertion without any recent changes 
in severity. The individual with AE-COPD complained 
of progressive cough, purulent expectoration as well as 
dyspnea at rest and symptoms of acute gastroenteritis. The 
two patients with GOLD stages II and III had not experi-
enced AE-COPD within the last 12 months preceding the 
study inclusion. The patient with stable COPD and GOLD 
stage IV reported three exacerbations per year. Sputum 
microbiology was sterile in two subjects, while Candida 
albicans was detected in the other subject. Viral coinfections 
with RSV (6.5 × 103 viral copies, detected in the induced 
sputum of the AE-COPD patient) and RSV and inﬂ  uenza 
virus A (3.2 × 103 and 3.8 × 104 viral copies, respectively, 
both detected in nasal lavage samples) were existent in two 
of the three patients.
Sequencing of positive PCR products
Sequence determination of the three positive HBoV PCR 
products revealed a 99% sequence identity with the 
Swedish strains ST1 and ST2 and between the nucleotide 
sequences obtained from the years 2000 and 2002. Nucleotide 
sequences of ampliﬁ  ed PCR products were deposited into 
GenBank as a result of this study [GenBank: FJ156726-
FJ156728].
Discussion
In this retrospective study of a prospectively recruited, 
case-controlled cohort we found HBoV detection to be infre-
quent in adult hospitalized patients with acute exacerbation 
and stable COPD during the years 1999 to 2003 in the urban 
region of central Ruhr area, Germany. In total, HBoV DNA 
was detected in three of 202 patients (1.5%) only. It was found 
both in acute exacerbation (0.8%, 1/134) and stable disease 
(2.9%, 2/68) as well as induced sputum and nasal lavage 
samples. These ﬁ  ndings suggest that HBoV may not be of 
clinical relevance in adult patients with AE-COPD and routine 
testing for HBoV in this population may not be warranted.
Data on HBoV infections in adults is limited.9,13,19–23,30 
Screening for respiratory viruses is not generally recom-
mended for adults with symptoms of lower respiratory tract 
infection,1,31 thus material for large-scale retrospective analy-
sis is hardly available. The very low frequency of overall 
HBoV detection found in our study is in agreement with other 
studies in adults. The initial investigation by Allander and 
colleagues did not detect HBoV in 112 adults with respiratory 
Table 2 Clinical characteristics of the three HBoV-DNA-positive patients
  Patient BHL1 Patient BHL2 Patient BHL3
COPD Status Acute Exacerbation Stable Stable
Age (years) 75 57 50
BMI (kg/m2) 26.8 25.8 47.2
Smoking behavior Nonsmoker Ex-smoker Active smoker
Pack years – 80 90
FEV1 (L) 1.6 0.9 1.5
FEV1 (% predicted) 56.4 27.6 47.1
FEV1/FVC 57.9 35.1 64.2
CRP (mg/dL) 4.1 0.7 1.0
Leukocytes/nL 9.2 10.4 11.8
Oral steroid dose 15 mg/day 15 mg/day None
ICS Yes Yes No
Note: Oral steroid dose in mg/day prednisone equivalent.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FEV1, forced expiratory volume in one second; FVC, forced 
vital capacity; ICS, inhaled corticosteroids.International Journal of COPD 2009:4 116
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symptoms at all.9 A large Thai study detected HBoV in 0.7% 
of subjects (6/834) aged 20 years or older (including 126 con-
trols) only.13 Two Italian studies found frequencies of 1.2% 
(1/84 between the years 2000 and 2006)21 and 1.4% (2/143)19 
in adult patients despite the use of different PCR assays (real-
time and single-round PCR, respectively). Notably, a very 
recent US-American study found the identical frequency 
of 1.5% in 273 adults.22 The only previous study explicitly 
including patients with AE-COPD found HBoV in one of 
126 (0.8%) adult patients with AE-COPD or pneumonia, a 
71-year-old Canadian male who had received oral steroids for 
the treatment of his exacerbation.20 Unfortunately this report 
covered one winter season (2002/2003) only and neither 
speciﬁ  ed the proportion of AE-COPD patients included nor 
provided any clinical details on the population.
In contrast to the reports mentioned above, which 
predominantly studied specimens representing the upper 
respiratory tract (nasal swabs or nasopharyngeal aspirates), 
our study investigated both induced sputum and nasal lavage 
samples. In a previous PCR-based study we demonstrated 
that AE-COPD requiring hospital admission was signiﬁ  -
cantly associated with the presence of common respiratory 
viruses. Induced sputum, which may more reliably reﬂ  ect the 
lower respiratory tract, had a higher viral yield than upper 
respiratory tract specimens in patients with AE-COPD.25 
HRV (36%), inﬂ  uenza virus A (25%), and RSV (22%) 
were most frequently detected, while in a similar study we 
recently found another emerging respiratory virus, HMPV, 
to be infrequent in AE-COPD as well (2.3%, 3/130, overall 
prevalence 1.3%, 3/229). However all of the three HMPV 
detections occurred in the AE-COPD group, making asymp-
tomatic carriage unlikely.7
The present study investigated the frequency of HBoV 
infection in four consecutive years with special care on 
avoidance of a seasonal selection bias by monthly recruit-
ment of both groups in a 2:1 case-control setup. We used 
an optimized HBoV PCR assay performing 50 cycles of 
single-round, hot-start PCR,29 which was sensitive enough 
to detect a single HBoV DNA copy per reaction. Sequencing 
of PCR products revealed a nucleotide identity of 99% 
between different samples and years. This ﬁ  nding of a 
limited genetic variation is in agreement with previous 
reports.9,23 In the present study viral coinfections, which 
were assessed by sensitive PCR assays, were existent in 
two of three HBoV-positive subjects (although specimens 
were not evaluated for the presence of some less common 
respiratory viruses like adenovirus, coronaviruses NL63 and 
HKU1, and parainﬂ  uenza viruses 1 and 2). This ﬁ  nding is 
consistent with the hypothesis that HBoV is carried at low 
copy numbers in some individuals and that its detection is 
enhanced, or the virus reactivated, by another respiratory 
infection.16
Due to the very low detection rate in our study, an 
analysis of a potential association between HBoV infection 
and distinct clinical features was not possible. Remarkably, 
the patient with AE-COPD who tested positive for HBoV 
suffered from concomitant acute gastroenteritis. HBoV 
has also been proposed to be a causative pathogen in acute 
gastroenteritis, but so far its etiologic role remains contro-
versial.32,33
Conclusion
This is the ﬁ  rst controlled study on the prevalence of HBoV in 
adult hospitalized patients with AE-COPD. We found HBoV 
at a very low frequency in patients with acute exacerbation as 
well as stable COPD, comparable to what has been reported 
in other adult study populations. Thus, a major role of HBoV 
infection as a common trigger of AE-COPD is unlikely.
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